Autophagy as a target for cancer therapy: new developments

Jennifer S Carew
Kevin R Kelly
Steffan T Nawrocki

The Department of Medicine and Institute for Drug Development, Cancer Therapy and Research Center at The University of Texas Health Science Center, San Antonio, TX, USA

Abstract: Autophagy is an evolutionarily conserved lysosomal degradation pathway that eliminates cytosolic proteins, macromolecules, organelles, and protein aggregates. Activation of autophagy may function as a tumor suppressor by degrading defective organelles and other cellular components. However, this pathway may also be exploited by cancer cells to generate nutrients and energy during periods of starvation, hypoxia, and stress induced by chemotherapy. Therefore, induction of autophagy has emerged as a drug resistance mechanism that promotes cancer cell survival via self-digestion. Numerous preclinical studies have demonstrated that inhibition of autophagy enhances the activity of a broad array of anticancer agents. Thus, targeting autophagy may be a global anticancer strategy that may improve the efficacy of many standard of care agents. These results have led to multiple clinical trials to evaluate autophagy inhibition in combination with conventional chemotherapy. In this review, we summarize the anticancer agents that have been reported to modulate autophagy and discuss new developments in autophagy inhibition as an anticancer strategy.

Keywords: autophagy, chloroquine, lucanthone, cancer, apoptosis

Introduction

Autophagy is an evolutionarily conserved cellular catabolic degradation process that is characterized by the formation of double-membrane vesicles (autophagosomes) that engulf cellular components targeted for destruction. Autophagic degradation is an important regulator of cellular homeostasis as this process mediates the turnover of defective organelles, misfolded or aggregated proteins, and certain long-lived molecules. Knockout animal studies demonstrated that some degree of basal autophagy is essential for viability as autophagy-deficient mice cannot survive the neonatal starvation period, and these mice die within one day of birth. Ex vivo studies demonstrating that autophagy-deficient cells are significantly more susceptible to starvation-mediated cell death triggered by serum or growth factor deprivation than their autophagy-competent counterparts provided further support for a critical role for autophagy in the regulation of cellular homeostasis. Autophagy is initiated by stress signals from the mammalian target of rapamycin complex 1 (mTORC1), which activates the kinase ULK1 (ATG1), and which then forms a complex with ATG13 and ATG17. Autophagosome formation occurs after mTORC1 activity is inhibited and requires class 3 phosphoinositide 3-kinase (PI3K) activity as vacuolar sorting protein 34 forms a complex with Beclin-1. Microtubule-associated protein light chain 3 (LC3) is incorporated into the membrane by ATG7 and ATG3. LC3 recruits adaptor proteins such as p62 and NIX that recognize protein aggregates and damaged organelles and...
recruits them into the autophagosome. Autophagosomes subsequently fuse with lysosomes to form autolysosomes, and their cargo is degraded by a number of different lysosomal proteases including the cathepsins (Figure 1). In this review, we will summarize what is currently known regarding the regulation of autophagy, the role(s) of autophagy within the context of malignancy, and the therapeutic implications of autophagy activation versus autophagy inhibition in the treatment of cancer.

**Established regulators of autophagy**

**Mammalian Target of Rapamycin (mTOR)**

Although a number of signaling pathways have been implicated in the control of autophagy, the most well characterized autophagy regulator to date is mTOR. mTOR functions as two multiprotein complexes, mTORC1 and mTORC2, and each has unique binding partners and differential sensitivity to rapamycin and related compounds. mTORC1 is able to form a complex with multiple binding partners, and its activity is inhibited by rapamycin and related drugs including temsirolimus/CCI-779, everolimus/RAD001, and ridaforolimus/AP23573. The PI3K/AKT/mTOR signaling cascade is an essential regulator of protein translation and cell proliferation. Its activity can be stimulated by growth factors and nutrients, although this pathway is constitutively active in many cancer types.

Constitutive PI3K/AKT signaling in malignant cells is frequently a consequence of mutations in PI3K or upstream regulators of this pathway. Activated AKT promotes mTOR activity, and the stimulation of autophagy. The activation of autophagy serves to maintain cell survival under nutrient-deficient conditions, as the breakdown of cellular components generates essential metabolic fuel. Similarly, increased autophagic activity has been frequently observed in malignant cells in response to treatment with therapeutic mTOR inhibitors, and this has been hypothesized to significantly reduce their clinical activity.

**Beclin-1**

Beclin-1 is a member of the BCL-2 homology domain 3 (BH3) containing proteins, which have been well characterized as critical regulators of apoptosis. Beclin-1 is widely expressed in human tissues and is primarily localized to the endoplasmic reticulum, mitochondria, and the perinuclear membrane. Earlier studies demonstrated that the evolutionarily conserved domain of Beclin-1 is required for its proautophagic and tumor suppressive functions. The BH3 domain of Beclin-1 facilitates its self-association and its interactions with antiapoptotic members of the BCL-2 family. Recent studies have identified death-associated protein kinase (DAPK) as an important regulator of Beclin-1-mediated autophagy. Phosphorylation of Beclin-1 by DAPK causes it to dissociate from BCL-2 family members and this event promotes the
induction of autophagy. Interestingly, DAPK has also been shown to have a Beclin-1 independent function in the stimulation of autophagy through its interactions with LC3.

A separate investigation defined an indirect role for c-Jun N-terminal kinase 1 (JNK1) in the control of Beclin-1-associated autophagy by demonstrating that JNK-mediated phosphorylation of BCL-2 disrupts its binding to Beclin-1, which ultimately leads to the induction of autophagy. Ubiquitination also appears to contribute to the control of Beclin-1 function as its ubiquitination on lysine 63 was recently shown to facilitate its self-association and the formation of autophagosomes. Additional studies are required to fully elucidate the finer mechanistic details regarding how different phosphorylation and ubiquitination events specifically control Beclin-1’s function within the context of autophagy. Finally, the generation of Beclin-1-deficient mice established the essential function of Beclin-1-mediated autophagy during embryonic development, as its loss yields an embryonic lethal phenotype characterized by death at embryonic day 7.5 or earlier due to impaired proamniotic canal closure.

p53

The identification of the p53 transcriptional target damage-regulated autophagy modulator (DRAM) established a role for p53 in the regulation of autophagy. Initial studies demonstrated that DRAM1 expression was induced by DNA-damaging agents in a p53-dependent manner. Indications that DRAM1 may play a role in autophagy were initially revealed by its lysosomal localization. Mechanistic studies designed to elucidate DRAM1’s function(s) demonstrated that its expression promotes autophagosome formation. A subsequent study showed that DRAM could also be activated by the p53 related protein, p73. However, unlike p53, p73 retained its ability to induce autophagy in a manner that was independent of DRAM1 expression. These findings indicated that other p53/p73 transcriptional targets may be able to compensate for the loss of DRAM1 with respect to the regulation of autophagy.

Several studies have identified a number of candidate transcriptional targets that may contribute to the control and execution of autophagy. Additional research is required to define their individual roles and significance. Interestingly, more recent rigorous analyses of DRAM1 and its functions showed that DRAM1 encodes multiple isoforms and also belongs to a family of five related proteins, whose functions and transcriptional regulation remain to be fully elucidated. Ongoing studies will likely clarify these issues.

Autophagy in cancer

The roles of autophagy within the context of cancer remain somewhat controversial and appear to be quite divergent in the pre- and postmalignant states. Numerous studies have established that autophagy is an essential process in tumor suppression. The first evidence of this came from a study of mice with Beclin-1 haploinsufficiency (BECN1), which displayed a significantly higher frequency of spontaneous malignancies (leukemias, lymphomas, and tumors of the lung and liver) as compared with their wild-type counterparts. As mentioned earlier, deletion of both Beclin-1 alleles induces embryonic lethality. These phenotypic characteristics most likely result from the aberrant accumulation of organelles and specific proteins such as ubiquitinated keratins and the autophagy cargo adaptor p62 due to compromised autophagic degradation. In particular, abrogation of p62 turnover due to the disruption of autophagy has been shown to lead to activation of the DNA damage response, disruption of cellular redox status, accumulation of defective mitochondria, increased susceptibility to degenerative and inflammatory diseases, and enhanced tumorigenicity. Specifically, several clinical correlative studies have provided additional support for a role for Beclin-1 in tumor suppression. The loss of Beclin-1 expression is linked to a poor prognosis in patients with solid malignancies. Low/deficient Beclin-1 expression is associated with shorter overall survival in patients with colon cancer and squamous-cell carcinoma of the esophagus. Conversely, elevated Beclin-1 levels appear to be associated with a favorable prognosis in patients with high-grade glioblastomas or hepatocellular tumors.

However, a separate study of specimens from patients with nasopharyngeal tumors showed that high Beclin-1 expression was significantly correlated with poor outcomes. Similarly, two independent studies investigated LC3 expression levels and their potential correlation with clinical outcomes in patients with cancer. A study of melanoma in situ (MIS) and melanoma specimens showed significantly higher levels of expression of LC3 and greater numbers of autophagosomes in both tissue types as compared with normal melanocytes and early stage melanoma in situ, indicating that the elevation of autophagic activity may be a later event in disease pathogenesis. A larger assessment of LC3 levels in gastrointestinal tumors demonstrated overexpression of LC3 in more than 50% of all specimens analyzed. Interestingly, there was no clear link between LC3 levels and patient survival. Collectively, these findings outline a potential role for autophagy as a contributor to the malignant phenotype, but suggest that caution should be taken regarding
the potential use of any individual autophagy factor as a predictive biomarker.

The majority of pertinent studies conducted to date indicate that autophagy likely contributes to tumor suppression in healthy cells. However, it appears that autophagy may instead promote the pathogenesis of established malignancies by providing cancer cells with a mechanism to generate alternative sources of metabolic fuel via protein recycling, which facilitates their survival in nutrient/oxygen-deficient conditions.\(^{46,47}\) Considering that nutrient and oxygen deprivation are hallmark features of the tumor microenvironment, cancer cells may have an increased dependency upon autophagy for their survival. A number of studies have provided support for this hypothesis. For example, hypoxia-inducible transcription factor 1α (HIF-1α), which is constitutively active in many tumor types, was shown to promote BCL-2/adenovirus E1B 19kDa-interacting protein (BNIP3L)-dependent autophagy.\(^{48,49}\) Recent evidence suggests that hypoxic conditions may also trigger autophagy through a HIF-1α-independent mechanism that involves activation of the unfolded protein response.\(^{50}\) Unfolded protein response-induced autophagy may serve as a mechanism to reduce endoplasmic reticulum energy consumption while simultaneously generating metabolic fuel from the catabolism of endoplasmic reticulum membranes and other organelles such as mitochondria.\(^{51}\)

While most published studies support a prosurvival role for autophagy in cancer pathogenesis, there is also evidence for the induction of autophagy during the cell death process. In fact, some investigators in the field believe that autophagy can function as a unique caspase-independent mechanism of cell death that is distinct from apoptosis and necrosis as the minimum number of organelles or cellular components are degraded as required to support cell survival.\(^{52}\) Others feel that autophagy associated with cell death likely reflects an attempt by cancer cells to survive the stress stimuli that initiated their death process and that it impedes rather than accelerates the efficiency of apoptotic/necrotic execution. The specific implications of this phenomenon are likely to be context-dependent and vary between in vitro and in vivo settings. Additional research is required in order to draw definitive conclusions. These reviews provide an excellent summary of what is currently known regarding autophagy as a potential mechanism of cell death.\(^{53,54}\)

A number of studies have provided strong evidence implicating autophagy as a process that increases the survival capacity of both normal and malignant cells under stressful and metabolically challenging conditions both in culture and in the in vivo microenvironment.\(^{2,47,55}\) Genetic impairment of autophagy significantly diminishes the ability of cells to withstand nutrient deprivation and confers an accelerated rate of cell death in response to these conditions as compared with experimental controls.\(^{38}\) Although most evidence suggests that the survival advantage of autophagy-competent versus autophagy-deficient cells in the face of oxidative, genotoxic, or metabolic stress is derived from the autophagy-mediated catabolic generation of alternative energy sources, it is possible that other aspects of autophagy function could also promote cell survival and/or resistance to cell death. Ongoing research will likely define additional roles for autophagy in the regulation of cell survival.

Although low nutrient levels and hypoxia have been shown to trigger autophagy in cancer cells, numerous studies have shown that autophagy may also be stimulated in response to treatment with anticancer agents and radiation therapy. A wide array of therapeutic modalities with diverse mechanisms of action have been reported to induce autophagy including mTOR inhibitors, arsenic trioxide, etoposide, histone deacetylase (HDAC) inhibitors, tamoxifen, temozolomide, tyrosine kinase inhibitors, proteasome inhibitors, and ionizing radiation (Table 1).\(^{56-62}\) Based on earlier studies that showed that autophagy can represent both an alternative cell death pathway and a mechanism that promotes survival, autophagy is frequently viewed as a “double-edged sword.”

The role that autophagy plays following chemotherapy remains highly controversial. It is possible that the induction of autophagy may contribute to the efficacy of some anticancer agents; conversely, it could also facilitate cell survival by maintaining bioenergetics following exposure to chemotherapeutic agents.\(^{1}\) In order to better define the role of autophagy in the regulation of sensitivity to cancer therapeutics, investigators have quantified the impact of autophagy inhibition on the efficacy of numerous anticancer agents, including vorinostat, cyclophosphamide, and imatinib.\(^{56,57,59,60,63}\) The overwhelming majority of relevant preclinical studies have demonstrated that disruption of autophagy significantly augments the efficacy of most classes of anticancer agents.\(^{56–59,63}\) These studies suggest that autophagy inhibition may be an effective approach worthy of further investigation with broad applications in cancer therapy.

**Therapeutic modulation of autophagy: new developments**

As mentioned earlier, inhibition of autophagy in preclinical models increases the sensitivity of tumors to diverse
Recent preclinical studies have identified two new autophagy inhibitors with potential clinical utility in cancer therapy, and presented with some advantages associated with CQ/HCQ. The first agent, lucanthone (Miracil D), is an existing drug that has been used for many years for the treatment of schistosomal parasites. Earlier investigations have shown that lucanthone inhibits topoisomerase 2 activity, as well as the activity of AP endonuclease, a critical regulator of DNA base excision repair. These findings prompted the evaluation of lucanthone as a potential sensitizer to chemotherapy and radiation. A more recent study defined a novel mechanism of action for lucanthone that includes the inhibition of lysosomal function and the induction of apoptosis.

These collective findings provide a strong rationale for the need for additional inhibitors of autophagy.

### Table 1: Selected agents that modulate autophagy

<table>
<thead>
<tr>
<th>Drug class</th>
<th>Agent</th>
<th>Target</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Autophagy inducers</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>mTOR inhibitors</td>
<td>Temsirolimus&lt;sup&gt;70&lt;/sup&gt;</td>
<td>mTOR</td>
<td>Approved (RCC)</td>
</tr>
<tr>
<td></td>
<td>Sirolimus&lt;sup&gt;51&lt;/sup&gt;</td>
<td></td>
<td>Approved (Kidney transplants)</td>
</tr>
<tr>
<td></td>
<td>Everolimus&lt;sup&gt;73&lt;/sup&gt;</td>
<td></td>
<td>Approved (RCC)</td>
</tr>
<tr>
<td>HDAC inhibitors</td>
<td>Vorinostat&lt;sup&gt;73&lt;/sup&gt;</td>
<td>HDACs</td>
<td>Approved (CTCL)</td>
</tr>
<tr>
<td></td>
<td>Panobinostat&lt;sup&gt;74&lt;/sup&gt;</td>
<td></td>
<td>Phase 3</td>
</tr>
<tr>
<td>Proteasome inhibitors</td>
<td>Bortezomib&lt;sup&gt;75&lt;/sup&gt;</td>
<td>Proteasome</td>
<td>Approved (MM, MCL)</td>
</tr>
<tr>
<td></td>
<td>NPI-0052&lt;sup&gt;76&lt;/sup&gt;</td>
<td></td>
<td>Phase 1</td>
</tr>
<tr>
<td>Tyrosine kinase inhibitors</td>
<td>Imatinib&lt;sup&gt;76–78&lt;/sup&gt;</td>
<td>BCR-ABL, KIT, PDGFR</td>
<td>Approved (CML, GIST)</td>
</tr>
<tr>
<td></td>
<td>Dasatinib&lt;sup&gt;79&lt;/sup&gt;</td>
<td>BCR-ABL, SRC</td>
<td>Approved (CML)</td>
</tr>
<tr>
<td></td>
<td>Sorafenib&lt;sup&gt;80&lt;/sup&gt;</td>
<td>Multi (VEGFR, RAF, KIT)</td>
<td>Approved (RCC, HCC)</td>
</tr>
<tr>
<td></td>
<td>Lapatinib&lt;sup&gt;81&lt;/sup&gt;</td>
<td>EGFR, HER2</td>
<td>Approved (Breast cancer)</td>
</tr>
<tr>
<td>Estrogen receptor antagonist</td>
<td>Tamoxifen&lt;sup&gt;82&lt;/sup&gt;</td>
<td>Estrogen receptor</td>
<td>Approved (Breast cancer)</td>
</tr>
<tr>
<td>Antibodies</td>
<td>Rituximab&lt;sup&gt;83&lt;/sup&gt;</td>
<td>CD20</td>
<td>Approved (Lymphoma)</td>
</tr>
<tr>
<td></td>
<td>Panitumumab&lt;sup&gt;84&lt;/sup&gt;</td>
<td>EGFR</td>
<td>Approved (Colon cancer)</td>
</tr>
<tr>
<td></td>
<td>Cetuximab&lt;sup&gt;85&lt;/sup&gt;</td>
<td>EGFR</td>
<td>Approved (Colon and head/neck cancer)</td>
</tr>
<tr>
<td>Alkylating agents</td>
<td>Temozolomide&lt;sup&gt;86&lt;/sup&gt;</td>
<td>DNA</td>
<td>Approved (Glioblastoma)</td>
</tr>
<tr>
<td>BH3 mimetics</td>
<td>GX15-070&lt;sup&gt;80&lt;/sup&gt;</td>
<td>Bcl-2</td>
<td>Phase 2</td>
</tr>
<tr>
<td></td>
<td>ABT737&lt;sup&gt;87&lt;/sup&gt;</td>
<td></td>
<td>Preclinical</td>
</tr>
<tr>
<td><strong>Autophagy inhibitors</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aminothiols</td>
<td>Chloroquine&lt;sup&gt;16,59,63&lt;/sup&gt;</td>
<td>Lysosome</td>
<td>Approved (Malaria)</td>
</tr>
<tr>
<td></td>
<td>Lys05&lt;sup&gt;69&lt;/sup&gt;</td>
<td></td>
<td>Preclinical</td>
</tr>
<tr>
<td></td>
<td>Hydroxychloroquine&lt;sup&gt;56&lt;/sup&gt;</td>
<td></td>
<td>Approved (Malaria, systemic lupus erythematosus, rheumatoid arthritis)</td>
</tr>
<tr>
<td>Thioxanthenones</td>
<td>Lucanthone&lt;sup&gt;18&lt;/sup&gt;</td>
<td>Lysosome, topoisomerase 2, AP endonuclease</td>
<td>Approved (Schistosomiasis)</td>
</tr>
</tbody>
</table>

**Abbreviations:** mTOR, mammalian target of rapamycin; RCC, renal cell carcinoma; HDAC, histone deacetylases; CTCL, cutaneous T-cell lymphoma; MM, multiple myeloma; MCL, mantle cell lymphoma; PDGFR, platelet-derived growth factor receptor; CML, chronic myelogenous leukemia; GIST, gastrointestinal stromal tumor; VEGFR, vascular endothelial growth factor receptor; HCC, hepatocellular carcinoma; EGFR, epidermal growth factor receptor.
within the context of cancer. Based on the currently available data in the literature, it is highly likely that the cellular consequences of autophagy induction are cell type-specific and treatment-dependent.

Several key issues that need to be better addressed experimentally include elucidating the individual roles of oncogenes in the regulation of cellular autophagy activity, defining the impact of the tumor microenvironment on autophagy function, and determining the most effective approaches to therapeutically target autophagy for cancer therapy. Of particular interest related to the latter issue regarding the modulation of autophagy as an anticancer strategy, numerous studies have demonstrated that the pharmacological and/or genetic disruption of autophagy in combination with an array of anticancer agents or ionizing radiation yields significant therapeutic benefit in preclinical cancer models. These findings have been clinically translated and more than 20 clinical trials investigating the established inhibitors of autophagy CQ and HCQ in combination with a variety of conventional and targeted cancer therapies are currently ongoing. These studies will likely yield important information regarding the safety and preliminary efficacy of these autophagy inhibitors as potential augmenters of cancer therapy.

Given that the ocular toxicities and minimal single agent anticancer efficacy of CQ and HCQ may limit their future applications in cancer therapy, the discovery of novel autophagy inhibitors is a high priority. Lucanthone and Lys05 are two new and exciting autophagy inhibitors that have demonstrated superior efficacy and tolerability compared with CQ/HCQ in preclinical studies. Ongoing preclinical investigations of lucanthone as a novel autophagy inhibitor with potential clinical applications in combination with anticancer agents that induce this survival pathway.

A second novel inhibitor of autophagy that warrants further investigation as an anticancer agent is Lys05. This new drug shares some structural homology with CQ and was specifically designed to inhibit autophagy more effectively through the inclusion of two aminoquinoline rings, a triamine linker, and C-7 chlorine.69 Lys05 is a water-soluble compound that accumulates more readily within the lysosome and has improved deacidification effects compared with HCQ. Similar to lucanthone, Lys05 displayed significantly higher anticancer activity than CQ/HCQ in preclinical models without inducing significant observable toxicity. Additional studies are planned to further investigate the therapeutic anticancer potential of Lys05 as a novel inhibitor of autophagy.

## Conclusion and future directions

Defining the role(s) of autophagy in malignant pathogenesis and in the regulation of therapeutic sensitivity is an important and challenging endeavor. A plethora of studies conducted to date have clearly shown that the induction of autophagy can be associated with both the execution of cell death as well as the protection from prodeath stimuli including metabolic stress and treatment with anticancer agents. These observations have generated many important scientific questions and opened up new fields of autophagy-related investigation within the context of cancer. Based on the currently available data in the literature, it is highly likely that the cellular consequences of autophagy induction are cell type-specific and treatment-dependent.

### Table 2 Selected clinical trials with the autophagy inhibitor HCQ

<table>
<thead>
<tr>
<th>Tumor type</th>
<th>Identifier</th>
<th>Intervention</th>
<th>Phase</th>
<th>Sponsors</th>
</tr>
</thead>
<tbody>
<tr>
<td>Solid tumors</td>
<td>NCT01023737</td>
<td>HCQ + Vorinostat</td>
<td>1</td>
<td>CTRC at UTHSCSA, Merck, NCI</td>
</tr>
<tr>
<td>Multiple myeloma</td>
<td>NCT00568880</td>
<td>HCQ + Bortezomib</td>
<td>1/2</td>
<td>U Penn, Millennium</td>
</tr>
<tr>
<td>Brain, CNS tumors</td>
<td>NCT00486603</td>
<td>HCQ + Temozolomide/radiation</td>
<td>1/2</td>
<td>U Penn, CTEP, NCI</td>
</tr>
<tr>
<td>Solid tumors</td>
<td>NCT00714181</td>
<td>HCQ + Temozolomide</td>
<td>1</td>
<td>U Penn, Merck</td>
</tr>
<tr>
<td>Solid tumors</td>
<td>NCT00909831</td>
<td>HCQ + Temsirolimus</td>
<td>1</td>
<td>U Penn, Pfizer</td>
</tr>
<tr>
<td>Renal cancer</td>
<td>NCT01510119</td>
<td>HCQ + RAD001</td>
<td>1/2</td>
<td>U Penn</td>
</tr>
<tr>
<td>Colorectal cancer</td>
<td>NCT01206530</td>
<td>HCQ + FOLFOS/Bevacizumab</td>
<td>1/2</td>
<td>U Penn</td>
</tr>
<tr>
<td>Pancreatic cancer</td>
<td>NCT01506973</td>
<td>HCQ + Gemcitabine/Abraxane</td>
<td>1/2</td>
<td>U Penn</td>
</tr>
<tr>
<td>Pancreatic cancer</td>
<td>NCT01128296</td>
<td>HCQ + Gemcitabine</td>
<td>1</td>
<td>U Pittsburgh</td>
</tr>
<tr>
<td>Renal cancer</td>
<td>NCT01144169</td>
<td>HCQ</td>
<td>1</td>
<td>U Pittsburgh</td>
</tr>
<tr>
<td>Prostate cancer</td>
<td>NCT00726596</td>
<td>HCQ</td>
<td>2</td>
<td>CINJ, NCI</td>
</tr>
<tr>
<td>Prostate cancer</td>
<td>NCT00786682</td>
<td>HCQ + Docetaxel</td>
<td>2</td>
<td>CINJ, NCI</td>
</tr>
<tr>
<td>Breast cancer</td>
<td>NCT00765765</td>
<td>HCQ + Ixabepolone</td>
<td>1/2</td>
<td>CINJ, NCI</td>
</tr>
<tr>
<td>Lung cancer</td>
<td>NCT00728845</td>
<td>HCQ + Bevacizumab, Carboplatin, Paclitaxel</td>
<td>1/2</td>
<td>CINJ, NCI</td>
</tr>
<tr>
<td>Solid tumors</td>
<td>NCT00813423</td>
<td>HCQ + Sunitinib</td>
<td>1</td>
<td>CINJ, CTEP, NCI</td>
</tr>
<tr>
<td>Colorectal cancer</td>
<td>NCT01006369</td>
<td>HCQ + Capecitabine, Oxaliplatin, Bevacizumab</td>
<td>2</td>
<td>U Med and Dent New Jersey, NCI</td>
</tr>
<tr>
<td>Solid tumors</td>
<td>NCT01266057</td>
<td>HCQ + Sirolimus, Vorinostat</td>
<td>1</td>
<td>MD Anderson Cancer Center</td>
</tr>
</tbody>
</table>

Abbreviations: HCQ, hydroxychloroquine; CTRC at UTHSCSA, Cancer Therapy and Research Center at University of Texas Health Science Center San Antonio; NCI, National Cancer Institute; CINJ, Cancer Institute of New Jersey; CTEP, Cancer Therapy Evaluation Program.
studies and planned clinical trials with luncanthone and Lys05 will provide critical information regarding their potential applications in cancer therapy.

Acknowledgments
This work was supported by funding from The Institute for Drug Development, Cancer Therapy and Research Center at The University of Texas Health Science Center at San Antonio, USA.

Disclosure
The authors report no conflicts of interest in this work.

References
74. Ellis L, Bots M, Lindermann RK et al. The histone deacetylase inhibitors LAQ824 and LBH589 do not require death receptor signaling or a functional apoptosome to mediate tumor cell death or therapeutic efficacy. **Blood.** 2009;114(2):380–393.
75. Ding WX, Ni HM, Gao W et al. Oncogenic transformation confers a selective susceptibility to the combined suppression of the proteasome and autophagy. **Mol Cancer Ther.** 2009;8(7):2036–2045.

